Differential diagnosis between Cushing's disease and ectopic ACTH syndrome often runs into difficulties at present. Since ovine corticotropin-releasing factor (o-CRF) was isolated by Vale et al. (1981) , the o-CRF test has been performed in normal subjects and patients with hypothalamo-pituitaryadrenal disorders. Plasma ACTH response to o-CRF in Cushing's disease was normal or exaggerated in vivo (Orth et al., 1982; Miiller et al., 1983; Pieters et al., 1983; Lytras et al., 1984; Kubo, 1985) and o-CRF stimulated ACTH release in the pituitary adenoma from the patients with Cushing's disease in vitro (Suda et al., 1984; Oosterom et al., 1984) . On the other hand, plasma ACTH responses to o-CRF in ectopic ACTH syndrome in vivo were reported to be less remarkable (Lytras et al., 1984) or absent (Muller et al., 1983; Chrousos et al., 1984; Lytras et al., 1984) 
Results
In vivo o-CRF stimulating test (Fig. 1) In the first trial, o-CRF caused little response of plasma ACTH and cortisol (Fig. 1,  open circle) , but, on retesting, plasma ACTH showed about a 1.4 fold increase (against the mean of two basal samples) 15 and 180min after o-CRF administration, and plasma cortisol about 1.2 fold at 120 min.
In vitro ACTH release (Figs. 2 and 3 ) Basal ACTH release in 4 hours measured on the 3rd, 7th, 12th and 29th day of culture declined rapidly (Fig. 2) .
On day 3, o-CRF at a concentration of 10-8M stimulated ACTH release by 33% (p<0.02) (Fig. 3a) . Dex, 10-7M, did not suppress the basal ACTH release but suppressed ACTH release by o-CRF (Fig. 3a) .
On day 7, o-CRF, 10-7M, again increased ACTH release by 65% and Dex, 10-6M, had no effect (Fig. 3b) . LVP, 1 mU/ml, caused a 3.7 fold increase in ACTH release.
Discussion
This patient had some remarkable features of Cushing's syndrome and u-17-0H-CS were suppressed by 50% with high-dose Dex and were hyperresponsive to metyrapone. Plasma ACTH and cortisol were increased with LVP. These results had supported the diagnosis of Cushing's disease. However, o-CRF caused no response or only a slight response of plasma ACTH or cortisol and there was no difference between the ACTH levels for bilateral inferior petrosal veins and an antecubital vein. The diagnosis of ectopic ACTH syndrome was finally confirmed by the facts as follow: (1) After the removal of a bronchial carcinoid tumor, the plasma ACTH level fell to the normal range and her clinical symptoms were lessened. (2) The ACTH concentration in the tumor was very high. (3) Immunohistochemical staining showed cells positive for ACTH. (4) ACTH release was found in cultured carcinoid cells.
Some patients with ectopic ACTH syndrome were reported to have some laboratory findings as in our patient that were identical to those seen in patients with Cushing's disease (Strott et al., 1968 However , the increase was relatively small in spite of much higher concentrations of CRF than in plasma in the in vivo CRF test (Kubo, 1985) , and this may explain the difference between in vivo and in vitro responses to o-CRF in this patient. Hirata et al. (1979) reported that rat median eminence (ME) extract stimulated in vitro ACTH secretion in medullary carci- noma of the thyroid and malignant epithelial thymoma from each of two patients with ectopic ACTH syndrome though rat ME extract contained possible nonspecific ACTH secretagogues other than CRF. Dex did not suppress the basal ACTH release in cultured carcinoid cells. The difference between in vivo and in vitro responses is inexplicable. However, Dex, 10-7M significantly suppressed in vitro ACTH release by 10-8M of o-CRF.
The in vivo and in vitro data of the present patient were incompatible with the presumption of Orth (1984) that ectopic ACTH-secreting carcinoid adenomas that responded to Dex would respond to o-CRF. Further analysis in many cases would be necessary to arrive at a definite conclusion concerning this problem.
